Evidence method
Level · gp.fundamentals.capex_revenue_ratio
5.95% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
LCTX · Dec 31, 2024
Lineage Cell Therapeutics, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000950170-25-036309General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-243.10% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
6.19% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.operating_margin
-226.11% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
131.30% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
53.45% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History16 statesHistory building
Sep 30, 20220/5 normalizedLevel 3Dec 31, 20220/6 normalizedLevel 3Mar 31, 20230/6 normalizedLevel 3Jun 30, 20230/6 normalizedLevel 3Sep 30, 20230/7 normalizedLevel 3Dec 31, 20230/7 normalizedLevel 3Mar 31, 20240/6 normalizedLevel 3Jun 30, 20240/6 normalizedLevel 3Sep 30, 20244/6 normalizedLevel 3Dec 31, 20245/6 normalizedLevel 3Mar 31, 20255/6 normalizedLevel 3Jun 30, 20255/6 normalizedLevel 3Sep 30, 20256/6 normalizedLevel 3Dec 31, 20256/6 normalizedLevel 3Mar 31, 20266/6 normalizedLevel 3Jun 30, 20266/6 normalizedLevel 3
Period transition
What moved in the state?
- Previous
- 2.96%
- Current
- 5.95%
- Delta
- 2.98%
- Previous
- -153.14%
- Current
- -243.10%
- Delta
- -89.96%
- Previous
- 203.29%
- Current
- 6.19%
- Delta
- -197.10%
- Previous
- -101.61%
- Current
- -226.11%
- Delta
- -124.49%
- Previous
- 83.91%
- Current
- 131.30%
- Delta
- 47.39%
- Previous
- 35.19%
- Current
- 53.45%
- Delta
- 18.25%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · LCTX Fundamental State →Transitioned To · LCTX CASH_GENERATION_DECREASED →Transitioned To · LCTX GROWTH_DECREASED →Transitioned To · LCTX PROFITABILITY_DECREASED →Transitioned To · LCTX R_AND_D_INTENSITY_INCREASED →Transitioned To · LCTX SBC_INTENSITY_INCREASED →Transitioned To · LCTX Fundamental State →Transitioned To · LCTX CAPEX_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.